MedTrace Logo

Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients

NCT01474122 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 265

Last updated 2025-02-04

Study results available
· View outcomes & findings →

Summary

The DUAL-2 study is designed as a multicenter, double-blind two-period study with an initial fixed 16-week Period 1, followed by a Period 2 of variable duration. All patients completing Period 1 continue on their original randomized treatment into Period 2, until the last randomized patient has completed Period 1.

Patients are randomized in a 1:1:1 ratio (macitentan 3mg: macitentan 10mg: placebo).

The primary objective is to demonstrate the effect of macitentan on the reduction of the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcers (DU).

Other objectives include:

* the evaluation of the efficacy of macitentan on hand functionality and DU burden at Week 16 in SSc patients with ongoing DU disease.
* the evaluation of the safety and tolerability of macitentan in these patients.
* the evaluation of the efficacy of macitentan on time to first DU complication during the entire treatment period.

Conditions

  • Digital Ulcers

Interventions

DRUG

Macitentan 3 mg

Macitentan 3-mg tablet once daily

DRUG

Macitentan 10 mg

Macitentan 10-mg tablet once daily

DRUG

Placebo

Placebo tablet matching macitentan tablet, once daily

Sponsors & Collaborators

  • Actelion

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2014-02-28
Completion
2014-02-28

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01474122 on ClinicalTrials.gov